Loss of muscle mass leads to the metabolic disturbances, decreased insulin action and signaling-IR, reduced gluconeogenesis, glucose intolerance, pronounced production of triacylglycerol, and exacerbation of proteolysis, which eventually lead to the vicious circle of further aggravation of IR, severity of NAFLD, and muscle consumption [34–36]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.